Axsome Therapeutics has three drugs on the market and five in the pipeline, with the potential to help some 150 million Americans suffering from brain disorders.When Herriot Tabuteau started a drug development company in 2012, he decided to do so differently. First, he’d focus on brain disorders, treatments for which are notoriously difficult to develop and whose efficacy can be hard to prove. And he’d be both CEO and the scientific founder, bringing to bear his dec­ades of experience investing in biotech s ...